Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CR-200-1
- Development stage
- Unknown
- Lead developer
- Currax Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CR-200-1 is an investigational, once-daily oral drug candidate being developed by Currax Pharmaceuticals for the treatment of obesity. Currently in Phase 1 clinical development, the program is designed to provide a simplified dosing regimen compared to existing weight management therapies, which often require multiple daily doses. Currax Pharmaceuticals, the developer of the twice-daily obesity medication Contrave (a combination of naltrexone and bupropion), is utilizing CR-200-1 to potentially improve patient adherence and therapeutic outcomes in chronic weight management through optimized delivery and formulation.
Beyond the preview
Go deeper on CR-200-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CR-200-1.